Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma: a Randomized, Double-blind, Double Dummy, Multicenter Study

NCT03095040 is registered in ClinicalTrials.gov with AnewPharma as lead sponsor.

NCT NCT03095040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03095040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma: a Randomized, Double-blind, Double Dummy, Multicenter Study
Lead sponsor
AnewPharma
Phase
Phase 3
Overall status
Unknown status
Start date
December 16, 2016
Completion date
December 31, 2021
Enrollment
390 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell cancer metastatic